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Viral infections are important causes of morbidity and mortality after allogeneic stem cell hematopoietic
transplantation (allo-HSCT). Although most viral infections present with asymptomatic or subclinical manifestations,
viruses may result in fatal complications in severe immunocompromised recipients. Reactivation of latent viruses,
such as herpesviruses, is frequent during the immunosuppression that occurs with allo-HSCT. Viruses acquired from
community, such as the respiratory and gastrointestinal viruses, are also important pathogens of post-transplant viral
diseases. Currently, molecular diagnostic methods have replaced or supplemented traditional methods, such as viral
culture and antigen detection, in diagnosis of viral infections. The utilization of polymerase chain reaction facilitates
the early diagnosis. In view of lacking efficacious agents for treatment of viral diseases, prevention of viral infections
is extremely valuable. Application of prophylactic strategies including preemptive therapy reduces viral infections
and diseases. Adoptive cellular therapy for restoring virus-specific immunity is a promising method in the treatment
of viral diseases.
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Viral infections are common complications after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). With
wide use of HLA-mismatch, unrelated and cord blood do-
nors as alternative sources of hematopoietic stem cells, and
anti-thymocyte globulin (ATG) as the standard prophylaxis
of graft versus host disease (GVHD) in HLA-mismatch
and unrelated donor transplantation, allo-HSCT recipients
are at increasing risk for viral infections [1-5]. Fortunately,
improvements in viral diagnostics, such as utilization of
polymerase chain reaction (PCR)-based molecular diag-
nostic methods as replacement of traditional methods, fa-
cilitate the early diagnosis of viral infections [6-8]. And
application of prophylactic and preemptive strategies
limits the reactivation of latent viruses and development
of viral diseases [9-11]. Immunotherapeutic strategies to
restore virus-specific immunity, such as virus-specific
cytotoxic T cells (CTL) and donor lymphocyte infusion
(DLI), have been used for the treatment of viral diseases* Correspondence: liuqifa628@163.com
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stated.[12-14]. These developments improve outcomes of viral
infections after allo-HSCT [15-17]. The aim of this article
is to review the current concepts of diagnosis, prevention
and treatment of viral diseases in the recipients of allo-
HSCT. A brief overview will be followed by a detailed dis-
cussion on common viral diseases and viruses.Epidemiology
In the recipients of allo-HSCT, the difference in the
reported incidence is due in part to asymptomatic or
subclinical manifestations in most of viral infections and
the changing epidemiology of viruses as well as differ-
ences in diagnostic methods [18-23]. Till now, large-
sampled epidemiological data on overall incidence of
viral infections are absent in the recipients of allo-
HSCT. The limited data show that community acquired
respiratory viruses (CARVs) and herpesviruses are the
most common pathogens [24-26]. Among the causes of
CARVs respiratory tract infections, a preponderance of
respiratory syncytial virus (RSV) and parainfluenza virus
(PIV) are reported, followed by influenza virus and human
metapneumovirus (HMPV) [19,20,27]. In herpesvirustd. This is an Open Access article distributed under the terms of the Creative
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varicella zoster virus (VZV) infections as well as cyto-
megalovirus (CMV) diseases have significantly decreased
because of the effective prophylaxis [24,25]. The reports on
human herpes virus (HHV)-6 diseases are increasing in
allo-HSCT recipients [28-32].
Risk factors for viral infections
In the recipients of allo-HSCT, most viral infections are
opportunistic and closely related with immune status.
Thus, factors influencing engraftment and immune re-
constitution all potentially impact viral infections. Per-
ipheral blood stem cell transplantation is associated with
fewer viral infections than bone marrow and cord blood
transplantation due to better hematopoietic and immune
reconstitution [33-35]. Compared with HLA-match re-
lated transplantation, HLA-mismatch related and unre-
lated transplantation have an increasing risk of viral
infections because immune reconstitution is delayed by
the intensified GVHD prophylactic strategy, such as the
use of ATG [18,36-38]. GVHD may delay immune re-
constitution and is considered an independent risk fac-
tor of viral infections [36]. In addition, other factors,
such as the serologic status of donors and recipients
before transplantation as well as the age of recipients,
may also affect the incidence of viral infections. For
example, CMV-seronegative recipients receiving graft
from CMV-seropositive donors are at high risk of CMV
diseases [24]. Children are high-risk population of CARVs
infections [26].
Diagnostic strategies
Generally, the diagnosis of viral diseases in immuno-
competent individuals is based on clinical manifestations
and laboratory examination. A definitive diagnosis re-
quires detection of specific virus in specimens obtained
from involved tissues and secretions as well as blood, or
even histopathologic evidences. However, such a defini-
tive diagnosis is frequently unnecessary or unavailable
due to the risk associated with the invasive procedure
(e.g. infection, bleeding) [25,39]. Thus, stratified diag-
nosis of viral infections and diseases based on diag-
nostic evidences is recommended [25,39]. The clinical
manifestations of viral diseases in immunocompromised
individuals, including transplant recipients may be differ-
ent with the immunocompetent population [40]. For in-
stance, fever does not always occur and the disseminated
diseases are more common [24,25,39]. Meanwhile, viral
diseases generally occur with or subsequently to other
transplant complications such as bacterial and fungal
infections [24,25]. For example, CMV gastrointestinal
disease is particularly difficult to diagnose because it fre-
quently presents together with gut GVHD, and diarrhea is
the same symptom of these two transplant complications[24]. Therefore, in the recipients of allo-HSCT, the diag-
nosis of viral diseases mainly depends on laboratory
examination.
Laboratory diagnostic methods mainly include viral
culture, serologic testing, antigen and nucleic acid detec-
tion [6]. Table 1 showed the common methods used in
diagnosis of viral infections. The golden standard for
diagnosis of most viral diseases is finding of specific
histopathological features and detection of virus in the
involved tissues. However, biopsy is often infeasible in
allo-HSCT recipients, considering that most viral dis-
eases occur at the early stages of transplantation with
concomitant thrombocytopenia or unstable vital sign.
Viral culture is unsuitable in the early diagnosis because
it routinely takes days to weeks and requires specific cell
lines [41]. Serologic testing requires finding of progres-
sive increasing in antibody to identify a recent infection.
Unfortunately, transplant recipients are usually unable
to mount sufficient antibody because of immunosup-
pression. Therefore, serology is less helpful for clinical
decision in the recipients of allo-HSCT [24-26]. Tech-
niques of antigen detection, including fluorescent antibody
assays and enzyme immunoassays, are rapid diagnostic
methods of which results can be available within hours.
But the limitation of these methods is poor sensitivity
compared with molecular techniques [26,42,43]. Ap-
plication of PCR technique in the detection of viral nu-
cleic acid rapidly develops the viral diagnostics [6]. In
theory, any virus can potentially be detected by PCR.
Now, real-time quantitative PCR (RQ-PCR) is replacing
traditional gel-based PCR because it can reflect the
changes of viral loads [7,44-47]. The availability of these
modern diagnostic tools facilitates early diagnosis and
timely intervention of viral infections. Currently, the
diagnosis of viral infections in the recipients of allo-
HSCT mainly relies on PCR-based methods. To investi-
gate new or uncommon pathogens, electron microscopy
or viral culture can be used. Although biopsy has the
aforementioned problems and risk, it is still required in
the diagnosis of some specific viral diseases, such as
EBV-associated post-transplant lymphoproliferative dis-
order (PTLD) [25,48].
Treatment strategies
Although multiple strategies have been used [17,24-26,39],
the treatment of viral diseases remains rather a challenge
because few agents are available and efficacious. In the re-
cipients of allo-HSCT, immunotherapeutic strategies to
restore virus-specific immunity, such as reducing immu-
nosuppressants, DLI and ex vivo generation of virus-
specific CTL, are now advocated in the treatment of viral
diseases [14,25,49]. However, reducing immunosuppres-
sants is unfeasible in many patients due to potential risk
of GVHD [24,25], and DLI is limited by unavailable stem
Table 1 Common methods used in diagnosis of viral infections after transplantation
Methods Sensitivity * Specificity# Time§ Virus Comments
Culture +++ ++++ + HSV, CMV, VZV, Influenza virus,
RSV, PIV, adenovirus
Gold standard
May take weeks before results return
Shell vial culture ++ +++ ++ HSV, CMV, VZV, Influenza virus,
RSV, PIV, adenovirus
Reduce the testing time compared
with culture








NA NA NA All are possible Detect viruses in tissue
Electron microscopy ++ NA ++++ All are possible Require facility and experienced staff
Serology NA NA NA NA Less helpful in diagnosis
* “+” –“++++” indicated low sensitivity to high sensitivity; # “+” –“++++” indicated low specificity to high specificity; § “+” –“++++” indicated long testing time to
short testing time. NA indicated not applicable.
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note, these adoptive cellular therapies are only proven effi-
cacious for a few viruses, such as CMV, EBV and
adenovirus [12,50,51]. Early intervention has a dramatic
influence upon survival and may reduce the extent of
permanent injury in survivors [20,52,53]. For example, in
patients with CARVs infections, treatment is more effect-
ive if started prior to development of lower respiratory
tract infection (LRTI) or respiratory failure [26,54,55].
Our data showed that the patients with EBV fever with-
out tissue involvement had better treatment response
than those with end-organ diseases or PTLD [4].
Prophylaxis strategies
Since specific therapy is limited to only several antiviral
agents, prevention of viral infections is crucial to reduce
the incidence and mortality of viral diseases. According
to the different periods of transplantation, the strategies
might be divided to prophylaxis pre-transplantation,
during transplantation and post-transplantation. Before
transplantation, selection of virus-seronegative stem cell
donors for seronegative recipients, and decreasing virus
loads in virus-seropositive donors and recipients should
be considered. During transplantation, the strategies of
conditioning and GVHD prophylaxis should be chosen
prudently to minimize the delay of immune reconstitution.
After transplantation, prophylaxis should be performed
throughout the risk period such as pre-engraftment and
GVHD. The incidence of HSV and VZV infections has
decreased from 80% to lower than 5% in the recipients
of allo-HSCT receiving antiviral prophylaxis throughout
the risk period [25,56]. Preemptive therapy for reactivation
of some latent viruses, such as CMV and EBV has been
demonstrated to reduce the progression of viral diseases
[24,25]. Vaccination, such as Measles–Mumps–Rubellaand VZV vaccine, seems useful to prevent corresponding
viral infections [57,58]. Influenza virus vaccine is sug-
gested to be given to the recipients prior to each influ-
enza season [59].
Viral diseases after HSCT
Respiratory diseases
Respiratory diseases after HSCT are mainly caused by
CARVs [60,61]. Other viruses, such as herpesviruses and
adenovirus, may also result in respiratory infections
[61,62]. Majority of the patients present with upper re-
spiratory infection, and 18-44% of these patients may
progress to lower respiratory infection with mortality of
23-50% [18-21,23,63]. The incidence of respiratory diseases
after allo-HSCT ranges from 3.5% to 29% [20,64], and the
incidence of viral pneumonia is 2.1-14% [4,20,64-66]. Typ-
ical clinical manifestations include fever, cough, myalgias.
Dyspnea is an important symptom of viral pneumonia.
Some of CARVs infections show a pronounced seasonality.
For example, RSV and influenza virus reach a peak inci-
dence during the winter and spring [19]. CARVs may also
result in epidemic outbreak in the wards. Herpesvirus
pneumonia is usually caused by reactivation of latent vi-
ruses which occurs in severe immunosuppression such as
early period of transplantation and GVHD [2,67,68].
Encephalitis /meningitis
In immunocompetent individuals, herpesviruses are the
most frequent pathogens in sporadic viral encephalitis/
meningitis. A retrospective study from Schmidt-Hieber
et al. showed that viral encephalitis was mainly caused
by human herpes virus (HHV) -6, followed by EBV, HSV,
JC virus, CMV, VZV in the recipients of allo-HSCT [69].
Our data showed that herpesvirus-associated encephalitis
was mainly caused by EBV followed by HSV, CMV and
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increasing [69]. The incidence of viral encephalitis after
allo-HSCT was 1.2% in a retrospective study [69]. Our
results revealed that the incidence of herpesviruses-
associated encephalitis/meningitis was 6.3% [70]. In the
recipients of allo-HSCT, viral encephalitis/meningitis
usually occurs within 100 days post-transplantation. Clin-
ical manifestations of viral encephalitis/meningitis are di-
verse, including fever, changes of consciousness, seizures,
palsy of brain nerves and psychiatric disorders; but men-
ingeal irritation is not common compared with healthy
population [69]. The mortality of viral encephalitis/
meningitis ranges from 0% to 80%, depending on virus
types and timing of diagnosis and treatment [69,71].
Gastroenteritis
Rotavirus and norovirus are considered main causes of
viral gastroenteritis. Currently, adenovirus and CMV
are increasingly recognized as important pathogens
of viral gastroenteritis in the recipients of allo-HSCT.
Astrovirus-associated gastroenteritis which usually oc-
curs in children is rarely observed in the recipients of
allo-HSCT [72]. Few data are available on the incidence
of viral gastroenteritis after allo-HSCT. Van Kraaij et al.
documented that 19% of HSCT recipients (including
allo- and auto-HSCT) developed viral gastroenteritis
[73]. Fortunately, the mortality caused by rotavirus and
norovirus-related gastroenteritis is rare [74-77]. The
most common clinical manifestation of viral gastro-
enteritis is diarrhea, followed by vomiting and nausea.
Rotavirus and norovirus infections are seasonal with a
peak incidence in winter. Most of the patients acquire
the viruses from community [74,77]. The median onset
time of adenovirus and CMVgastroenteritis are 60–90 days
after transplantation, and usually associated with acute
GVHD [76,78].
Hepatitis
Viral hepatitis is the third cause of hepatic impairment
in the recipients of allo-HSCT, and usually occurs in 3–
6 months after transplantation [79]. The most frequent
pathogens of viral hepatitis are hepatitis B virus (HBV)
and hepatitis C virus (HCV) [80,81]. Besides, other vi-
ruses such as CMV and HSV may also result in hepatitis
[24,25]. Hepatitis B and C can be caused by either virus
reactivation or blood transmission. Since the carriage
rates of HBV and HCV vary in different regions, the in-
cidence of viral hepatitis varies [81,82]. Increasing virus
loads in blood is valuable for diagnosis. Of note, the
diagnosis of viral hepatitis should be based on exclusion
of other transplant complications (e.g., sinusoidal ob-
struction syndrome [SOS] and GVHD). Attributed to
effective prophylaxis and antiviral treatment, the mortal-
ity of hepatitis B and C is low [81,83].Cystitis
Post-transplant cystitis usually present with hemorrhagic
cystitis (HC). According to onset time, HC is divided
into early-onset HC (within 48 hours of conditioning) and
late-onset HC (occurring after 48 hours). Early-onset HC
is often due to the toxicity of conditioning regimen such
as cyclophosphamide. It is reported that 11.6-42% of pa-
tients develop late-onset HC after transplantation [84,85].
Late-onset HC was considered to be related with reactiva-
tion of latent BK virus (BKV), but this association remains
controversial [86,87]. Some studies suggested that acute
GVHD might increase the risk of HC [87,88]. Recently,
adenovirus and CMV were suggested to be associated with
late-onset HC [88,89].
PTLD
PTLD is a life-threatening complication following allo-
HSCT. Approximately 90% of PTLD result from EBV-
driven B cell proliferation poorly controlled by a weakened
immune response. Recent data implicated that CMV and
HHV-6 might contribute to the development of PTLD
[90,91]. The incidence of PTLD varies from 0.5% to 22%,
depending on the number of risk factors [3,68,92-94]. In
the recipients of allo-HSCT, most of PTLD occur within
1 year post-transplantation, reaching a peak incidence
within 3 months [95-97]. Isolated nodal involvement is
the most common presentation. About 20% of patients
present with extranodal involvement, and isolated extra-
nodal involvement is not rare [93,96,98-100]. Clinical pre-
sentations of PTLD depend on location and the degree of
organ involvement. PTLD with extranodal involvement
usually have poor outcome. The mortality of PTLD is 50-
64% [68,94]. Delay of diagnosis and treatment is associated
with a high mortality (>90%) [96,101].
Other viral diseases
Bone marrow suppression is common in the recipients
of allo-HSCT. Graft failure is a fatal complication after
transplantation. Several viruses, such as CMV, EBV, HHV-
6 and adenovirus have been recognized the causes of bone
marrow suppression and graft failure [24,25,39,102]. The
diagnosis of virus-associated graft failure should be based
on pancytopenia, bone marrow hypoplasia, detection of
virus together with exclusion of GVHD, rejection and
relapse [102] .
Common viruses in allo-HSCT recipients
Herpesviruses
The known herpesviruses resulting in human diseases
include α- (HSV and VZV), β- (CMV, HHV-6,-7) and γ-
herpesviruses (EBV and HHV-8). Herpesvirus infections
are usually asymptomatic or subclinical in immunocom-
petent population. The virus becomes latent in infected
cells after primary infection. When immune system is
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result in symptomatic infections, even fatal complica-
tions [24,25]. The diagnostic methods of herpesvirus in-
fections were summarized in Table 2.
HSV
Up to 80% of the healthy population have history of
HSV-1 and −2 infections [25]. HSV-1 infection is more
common than HSV-2. After primary infection, the virus
becomes latent in the neuronal cells. Historically, 80% of
HSV-seropositive patient developed reactivation after
allo-HSCT without antiviral prophylaxis [104]. Fortu-
nately, the incidence of HSV reactivation has now de-
creased to 0-3% because of prophylactic acyclovir [56,105].
HSV causes a spectrum of diseases, such as herpes,
oesophagitis, bone marrow suppression, respiratory tract
diseases, hepatitis and encephalitis in the recipients of allo-
HSCT [25]. Due to the high rate of HSV reactivation,
prophylactic oral acyclovir has been administered routinely
in allo-HSCT recipients. Intravenous acyclovir should be
considered for patients with poor drug absorption [17,106].
Valacyclovir is an alternative prophylactic agent with good
bioavailability [107-109]. Acyclovir is recommended as the
therapy for severe mucocutaneous or visceral HSV disease
in transplant recipients [25]. Valaciclovir and famciclovir
are considered as alternatives for less serious manifesta-
tions of HSV diseases [25]. The recommended drug for
acyclovir-resistant HSV is foscarnet [17]. Cidofovir might
be effective to treat HSV infection which is resistant to
both acyclovir and foscarnet [110].
VZV
Varicella caused by primary VZV infection is a common
childhood disease. After primary infection, VZV estab-
lishes latency in the dorsal root ganglia in immunocom-
petent host. The reactivation of VZV results in herpes
zoster [111,112]. In the recipients of allo-HSCT, VZV is
also an important cause of viral encephalitis. VZV
immunization is advocated in recipients without a his-
tory of varicella. Varicella vaccine has been showed to be
safe in children with leukemia, but few data are available
in transplant recipients [106]. Besides, vaccination ofTable 2 Laboratory diagnosis of herpesviruses
Viruses Methods
HSV PCR(preferred); antigen detection [25]
VZV PCR(preferred); Immunofluorescent-antibody
staining [25]
CMV PCR(preferred); CMV antigen (pp65) detection
[24,103]
EBV PCR; immunohistochemistry or in situ hybridization
to detect EBV in biopsy specimens [25]
HHV6-8 PCR [24]VZV-seronegative individuals who may be in contact
with the patients during transplantation should be done
[25]. Zoster immune globulin (ZIG) and varicella-zoster
immune globulin (VZIG) are passive antibody prophy-
laxis in seronegative recipients after exposure to vari-
cella [113]. Acyclovir and valacyclovir prophylaxis were
proven effective in several trials [9,114-117]. Antiviral
therapy with acyclovir is recommended in the treatment
of VZV infection [25]. Acyclovir has been shown to reduce
the progression and dissemination of VZV infection
[118,119]. Treatment with brivudin or famiciclovir is
effective in immunocompromised population [120,121].
Foscarnet and cidofovir are alternative agents against
acyclovir-resistant VZV infection [122].
CMV
CMV infects 70-80% of the healthy individuals and
establishes latency in peripheral blood monocytes
and tissue macrophages. Till now, CMV remains one
of the most important viruses and causes of death in the
recipients of allo-HSCT. CMV-associated end-organ dis-
eases include pneumonia, enteritis, hepatitis, retinitis and
encephalitis, and so on; CMV syndrome is defined as
CMV-associated fever without sign of CMV end-organ
disease [24]. Majority of CMV infections are caused
by reactivation of virus which usually occurs within
3 months post-transplantation [8,24,78]. Approximately
75% of CMV-seropositive recipients develop CMV reacti-
vation, and 20-30% of these patients develop CMV dis-
ease without intervention [17,24]. Preemptive therapy
based on CMV antigenemia or DNA-emia significantly
reduces the development of CMV disease in allo-HSCT
patients [24,123]. However, the mortality of CMV disease
is more than 50% even with treatments [67,124]. The
diagnosis of CMV infection includes CMV viremia, CMV
syndrome and CMV end-organ disease [24]. Historically,
CMV antigen (pp65) detection was widely used in diag-
nosis of CMV infection. Recently, PCR is replacing anti-
genemia assay to be the preferred diagnostic method due
to higher sensitivity [24,103].
Preemptive therapy based on CMV viremia has be-
come the standard prevention of CMV diseases after
transplantation [24]. The first-line preemptive therapy
is ganciclovir with a minimum duration of 2 weeks
depending on whether CMV is detected at the end
of the course [24,125,126]. The main side effect of ganci-
clovir is bone marrow suppression which results in the
increase of bacterial and fungal infection [127,128].
Valganciclovir is an alternative with good bioavailability
[129-131]. Foscarnet and cidofovir are the second-
line prophylactic agents considering of drug-associated
toxicity [24].
Ganciclovir is the first-line treatment of CMV diseases.
The recommended therapy of CMV pneumonia is a
Lin and Liu Journal of Hematology & Oncology 2013, 6:94 Page 6 of 14
http://www.jhoonline.org/content/6/1/94combination of intravenous ganciclovir and high dose
immune globulin [24,124,132]. In view of toxicity and ef-
fective rate, cidofovir and foscarnet are used as second-
line therapy of CMV diseases [24]. Ganciclovir resistance
is uncommon and usually mediated through mutations
in the UL97 gene. Cidofovir is used in the treatment
of CMV disease which is resistant to ganciclovir and
foscarnet, with an effective rate of 50% [133]. Since
it has been known that specific immune response to
CMV is important to control reactivation, CMV-specific
CTL has been used in prophylaxis and treatment of CMV
viremia in several studies [50,51,134]. Leen et al. reported
that the response rate of CMV-specific CTL was 73.9% in
the treatment of CMV diseases after allo-HSCT [50].
EBV
Approximately 90% of healthy adults have been infected
by EBV. After primary infection, EBV is latent in B cells
(6, 8). Primary EBV infection or reactivation usually
induces asymptomatic infection or infectious mono-
nucleosis in immunocompetent people. However, EBV
results in a spectrum of diseases in the recipients of allo-
HSCT, ranging from fever, end-organ disease (pneumonia,
encephalitis/myelitis, and hepatitis) to PTLD [4]. Among
these diseases, PTLD is most common [4,25]. Our data
showed that the 3-year cumulative incidence of EBV dis-
ease were 15.6% in the recipients of allo-HSCT, with the
PTLD incidence of 9.9% [4]. EBV disease is usually caused
by reactivation of latent virus after allo-HSCT. After trans-
plantation, 14-65% of recipients developed EBV reactiva-
tion, depending on different risk factors that the recipients
have [37,68,135]. The diagnosis of EBV infection includes
EBV viremia, probable end-organ disease and proven end-
organ disease as well as PTLD [25].
Since rapid increase of EBV-DNA loads in blood is
considered to be related with subsequent EBV diseases
[136], routine monitoring of EBV viral loads is necessary
after transplantation [25]. Preemptive therapy based on
EBV-DNA loads in blood and risk factors for EBV dis-
ease has yielded good results [25]. Preemptive therapy is
now developing mainly in two directions: adoptive cellu-
lar therapy (EBV-specific CTL) and B-cell depletion with
monoclonal antibodies. EBV-specific CTL has been
demonstrated effective to prevent EBV disease in several
studies [135,137], but the production of CTL requires
time. Besides, reduction of immunosuppressants is an
ideal preemptive therapy, but frequently not available
due to the risk of GVHD. Rituximab is easily available
and has shown little toxicity [138]. Based on the above,
rituximab is recommended as the preferred preemptive
therapy, followed by reduction of immunosuppresants
and EBV-specific CTL in the European guidelines [25].
The therapeutic strategies of EBV disease include anti-
virus, restoration of T cell response and clearance of theEBV infected cells. Antiviral agents (e.g. acyclovir and
ganciclovir) can reduce EBV replication, but is not active
in PTLD presumably because that viral thymidine kinase
expression is low during lytic phase and lack during la-
tency [139,140]. Recently, a novel agent arginine butyr-
ate, which induces EBV thymidine kinase transcription,
has been shown in vitro to render latently infected EBV-
immortalized B cells susceptible to ganciclovir [139,140].
Treatments to restore T-cell reactivity include reduction
of immunosuppressants and adoptive cellular therapy
(CTL and DLI) [25]. Anti-CD20 monoclonal antibody
(rituximab) is used to clear EBV-infected B cells [25].
According to the European guidelines, rituximab is a
recommendation of highest priority for treatment of
PTLD; other first-line treatment includes reducing im-
munosuppressants, EBV-CTL and DLI [25]. Chemother-
apy is recommended as the second-line therapy [25].
The response rate of rituximab monotherapy was reported
44-69% whereas the relapse rate was 18-32% [141-144].
Compared with rituximab, adoptive cellular immunother-
apy has higher response rate (50-88%) and fewer relapse
(0%) [12,145,146]. Nevertheless, the utilization of adoptive
cellular therapy is limited by the aforementioned disadvan-
tages such as time and facilities required by CTL produc-
tion as well as potential risk of GVHD caused by DLI
[12,14,97,137,145]. Chemotherapy is reported to induce
remissions in 40-50% of the PTLD patients but with
significant treatment-related mortality and relapse rate
[141,147]. Therefore, in the ‘era of rituximab’, chemother-
apy is barely used unless for CD20-negative PTLD or
combination with rituximab [145]. To date, there are no
randomized trials to compare the efficacy between rituxi-
mab alone and rituximab combined with chemotherapy.
Trappe et al. [148] suggested that sequential first-line
treatment with rituximab followed by chemotherapy is
more efficacious than first-line rituximab monotherapy
followed by chemotherapy at progression or relapse. In
our study, we introduced a sequential therapeutic strategy
that is rituximab-based treatments followed by adoptive
cellular immunotherapy. The results revealed that this
strategy might elevate response rate and decrease the
relapse rate. Besides, this strategy might overcome the
drawback of long time frame to product EBV-CTL and
reduce the risk of GVHD caused by DLI. It remains a
matter of discussion that whether histology subtypes of
PTLD affect the outcome of rituximab-based treatments
[148,149]. The prognosis of PTLD with extranodal or
multi-organ involvement is dismal compared with iso-
lated nodal involvement [34,150]. Some studies suggested
that intrathecal rituximab is efficacious against PTLD
with CNS involvement [151-153]. Other therapeutic
options include local radiotherapy and operation, which
is mainly for the patients with significant compression
symptoms [145].
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quite limited. Rituximab seems efficacious to treat EBV
fever, with a response rate of 100% [4,154]. The treat-
ment strategies of EBV end-organ diseases are similar
with PTLD. However, the efficacy of rituximab mono-
therapy in patients with end-organ diseases seemed
poorer than those with PTLD [4].
HHV6-8
Approximately 50% of recipients develop HHV-6 reacti-
vation after transplantation [28,30]. HHV-6 diseases
include encephalitis, interstitial lung disease and delayed
engraftment [24,31]. Two small-sampled studies sug-
gested that ganciclovir might be effective to prevent
HHV-6 reactivation in allo-HSCT recipients [155,156].
However, no widely accepted prophylactic strategy is
recommended considering of the drug toxicity and the
low incidence of HHV-6 diseases [24]. Both ganciclovir
and foscarnet were reported to be effective against HHV-6
diseases [157].
HHV-7 infection/reactivation is infrequent in the recipi-
ents of allo-HSCT, and little information about HHV-7 dis-
eases is available. Therefore, prophylaxis and treatment of
HHV-7 infection remain unclear [24].
HHV-8 is recognized the cause of Kaposi’s sarcoma in
human immunodeficiency virus (HIV) infected patients
[158]. HHV-8 infection is rare in the recipients of allo-
HSCT, and usually results in non-malignant diseases
such as hepatitis, bone marrow suppression [159,160].
Currently, clinical data on prevention and treatment of
HHV-8 diseases after allo-HSCT are based on case re-
ports. Cessation of immunosuppressants and foscarnet
were used for treatment, and the efficacy requires fur-
ther study [161,162].
CARVs
CARVs, including orthymyxo- (influenza virus), paramyxo-
(RSV, PIV, HMPV), picorna- (human rhinovirus [HRhV]),
coronaviruses (HCoVs), human bocavirus (HBoV), and
polyomaviruses, are important pathogens of respiratory
tract infections in the recipients of allo-HSCT, [26]. Signifi-
cant overlap in clinical manifestations is observed in
CARVs infections, and atypical presentations are common.
Table 3 summarized the diagnostic methods and epi-
demiology of CARVs infections in the recipients of
HSCT. Antigen detection has a good specificity and a short
turn-around time of several hours, but a lower sensitivity
compared with PCR [59]. Currently, PCR for detection of
virus nucleic acid is preferred in diagnosis [26].
Infection control is the mainstay of prevention against
CARVs disease. Healthcare facilities and infection con-
trol measures, including isolation and strict protection
measures for healthcare workers and contacts, should be
applied to HSCT recipient [26,168]. Besides, recipientsand contacts should adhere to good personal hygiene.
Recipients should avoid contact with individuals with
CARVs respiratory infections in the hospital and the
community [26,168].
RSV
RSV is one of the most common respiratory pathogens in
most series including HSCT recipients. Limited data are
available on prevention of RSV infection. In some studies,
treating upper respiratory tract disease was effective to re-
duce the progression to pneumonia and improve the out-
come [26,163,164]. But some other reports did not confirm
this result [169,170]. Aerosolized ribavirin with or without
RSV-specific immunoglobulin or intravenous immuno-
globulin has been used to treat RSV pneumonia, with the
30-days survival of approximately 60% [19,54,64,163,171].
Treatment started before respiratory failure is associated
with improved outcome [19,54,64]. Intravenous ribavirin is
less effective but increases the side effects [55]. The efficacy
of palivizumab (an RSV-specific monoclonal antibody) in
HSCT recipients is not well defined [172,173].
PIV
PIV infection occurs throughout the year, with the highest
incidence in July and September [166]. The prophylactic
and therapeutic strategies against PIV infection remain a
matter of discussion. A large-sampled retrospective ana-
lysis suggested that aerosolized ribavirin with or without
intravenous immunoglobulin did not improve the outcome
of PIV pneumonia [165]. Elizaga et al. documented that
the effective rate of aerosolized ribavirin therapy was 100%
in the treatment of upper tract infections, whereas only
25% of patients with PIV pneumonia survived [166].
Influenza virus
To prevent influenza after transplantation, the European
guidelines recommended that vaccination should be per-
formed in HSCT recipients with seasonal influenza vaccine
[59]. Meanwhile, vaccination of healthcare workers and
close contacts with HSCT recipients is advocated [59].
Prophylaxis with oseltamivir seems useful after exposure
and during the period of influenza circulation [59,174]. M2
inhibitors, amantadine and rimantidine have no longer
been used for treatment due to widespread resistance
[175,176]. Neuraminidase inhibitors (oral oseltamivir or
inhalational zanamivir) are now the most widely used thera-
peutic agents for influenza, with an effective rate of 46-
100% [21,177,178]. Intervention initiated within 48 hours of
symptom onset was associated with reduced risk both for
pneumonia and the need for intensive care [21,179].
Other CARVs
At present, respiratory infections after HSCT caused
by HCoV, HMPV and HRhV have been increasingly
Table 3 CARVs infections after HSCT
Viruses Diagnostic methods Incidence of infection Progression to LRTI Mortality with LRTI
RSV PCR(preferred); Antigen detection; culture 2.2-5.8% [27,64,163] 17-84% [19,164] 7-83% [19,164]
PIV PCR(preferred); Antigen detection; culture Up to 17.9% [19,165] 50%[19,165] Up to 75% [166]
Influenza virus PCR(preferred); Antigen detection; culture 1.7-9.0% [19,21,23] 18-44% [19,21,23] 5-37% [19,21,23]
HMPV PCR(preferred); Antigen detection; 2.5-9% [26] 21-40% 33-40%
HRhV PCR(preferred); culture 22.3% [26] <10% [26] ?
HCoV PCR 11% [167] ? ?
HBoV PCR 2.1%[167] ? ?
?, absence of significant studies.
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16.2% of the recipients within 6 months after HSCT, in-
cluding 12% of LRTI; HMPV and HRhV was found in
5.4% and 2.7% of the recipients, respectively. The effica-
cious prevention and treatment of HMPV infections have
not been well described. Ribavirin and/or intravenous
immunogloblin were used to treat HMPV pneumonia in
several studies but the efficacy was not defined [26,180].
The prevention and treatment strategies of HRhV are lim-
ited by the lack of antiviral agents and clinical trials. There
are no recommendations on prophylaxis and treatment
due to absence of effective antiviral agents and appropriate
clinical studies [26].
Adenovirus
Adenovirus is increasingly recognized as an important
pathogen in immunocompromised individuals, especially
in the recipients of allo-HSCT. Adenovirus infection may
arise from either reactivation of latent virus or acquisition
from community. Contrary to self-limited infection in most
immunocompetent individuals, adenovirus causes lethal
end-organ or systemic diseases in immunocompromised
patients [39]. The incidence of adenovirus infection ranges
from 0-6% in adult allo-HSCT recipients, and half of these
patients developed adenovirus-associated diseases [18,22].
Adenovirus diseases include respiratory tract disease,
gastroenteritis, encephalitis, myocarditis, nephritis and
multiple organ involvement [18,22]. The mortality was
reported as high as 100% in adenovirus pneumonia [39]
and 61% in disseminated disease [181]. Now, PCR is the
standard diagnostic method of adenovirus infection [39].
Other diagnostic approaches include viral culture and
antigen detection [39].
Strict isolation and hygiene measures are advocated in
patients shedding the adenovirus to prevent horizontal
transmission and nosocomial outbreaks. Bordigoni et al.
[182] suggested cidofovir or DLI seemed encouraging
approaches to prevent adenovirus diseases, whereas riba-
virin and vidarabin were ineffective.
The efficacy of ribavirin is controversial in the treat-
ment of adenovirus diseases [182-184]. Several studiesdocumented that cidofovir was efficacious against adeno-
virus [75,76,182,185]. Considering of the insufficient im-
mune response to control adenovirus reactivation in the
patients, adenovirus-specific CTL seems a promising ther-
apy [186,187]. Leen et al. reported that the effective rate of
adenovirus-specific CTL was 77.8% in the recipients of
allo-HSCT [50]. In addition, reduction of immunosuppres-
sants is recommended for prophylaxis and treatment if
possible [18].
Gastroenteritis viruses
Rotavirus and norovirus are important pathogens of viral
gastroenteritis. The incidence of rotavirus infection is
6.7-11.5% in HSCT recipients, and death is rare [73,74].
Antigen detection as well as PCR is used in diagnosis of
rotavirus infection. At present, norovirus as a cause of
gastroenteritis after allo-HSCT is not well recognized
[188]. In pediatric HSCT recipients, the incidence of
norovirus-associated gastroenteritis was reported 12.9%
and no norovirus-associated mortality was observed [77].
Detection of norovirus RNA by PCR is the main diagnos-
tic evidence. Till now, little information is available about
prevention and treatment of rotavirus and norovirus in
the HSCT population. Oral immunoglobulin and nita-
zoxanide have been used in some studies [74].
Hepatitis viruses
Among hepatitis viruses, HBV and HCV are important
causes of hepatic impairment in the recipients of allo-
HSCT. Hepatitis virus-positive donor should be avoided
if alternatives exist.
For HBV-negative recipients, pre-transplant vaccin-
ation and HBV-specific immune globulin should be con-
sidered if the donors are HBV surface antigen positive.
For HBV-positive recipients, administration of antiviral
agents (i.e. lamivudine, famciclovir, Entecavir and adefovir)
pre- and post-transplantation is advocated to reduce HBV
replication [189,190].
Administration of ribavirin and interferon should be
considered to decrease or clear the viral loads before
transplantation in donors and recipients who are HCV
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used for treatment of hepatitis C [192,193].
Polyomaviruses
JC virus (JVC) which belongs to polyomavirus family is
known a pathogen of progressive multifocal leukoen-
cephalopathy (PML) in patients with HIV infection.
Reports of PML are quite rare in the recipients of allo-
HSCT [194]. Currently, treatment and prevention of JCV
in HSCT recipients remain unclear. Treatments consist-
ing of reduction of immunosuppressants, cidofovir and
serotonin-reuptake inhibitor as well as of JCV-specific
CTL infusion were demonstrated to produce a favorable
clinical outcome [194].
As mentioned, BKV as a member of polyomavirus
family is one of the causes of HC in allo-HSCT recipi-
ents. It is reported that ciprofloxacin and other fluoro-
quinolones may be useful to prevent BKV reactivation
[195]. Cidofovir has been used in the treatment of BKV-
associated HC [196,197].
Conclusion
Viral diseases are important complications after HSCT.
Development of viral diagnostics improves the early diag-
nosis and increases the diagnostic rate of some newly dis-
covered or uncommon viruses in allo-HSCT recipients.
Based on the pathogenesis of viral diseases, prophylaxis,
especially preemptive therapy can limit reactivation of
some latent viruses. Immunotherapeutic strategies to re-
store virus-specific immunity are attractive methods in the
treatment of viral diseases.
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